Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm QuantuMDx Buys NorthGene

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx said today it has bought identity testing company NorthGene in a stock and cash deal for an undisclosed amount.

Founded in 1995 as a spin-out of Newcastle University in the UK, NorthGene provides paternity and other relationship testing. QuantuMDx said that it plans to build out NorthGene's laboratory and staffing infrastructure, secure laboratory accreditation, and expand its test portfolio and DNA analysis services "to embrace medical, veterinary, and scientific research application."

NorthGene has been run as a not-for-profit with all revenues invested into medical research. QuantuMDx CEO Elaine Warburton said in a statement that her firm will continue "this philanthropic philosophy of using NorthGene surpluses to invest in advancing medical research for the benefit of global health."

Additionally, QuantuMDx will "play a key role in the testing and the commercial roll-out of our ground-breaking diagnostic and sequencing devices, which are now close to market," she added.

QuantumDx, also based in Newcastle, has a license from Nanosys to use nanowire field effect transistor biosensors for biomarker detection and sequencing applications.

The technology was developed in the laboratory of Harvard University chemistry professor Charles Lieber, a Nanosys co-founder. Target-specific nucleotides can be bound to an array of the nanowires to detect PCR-amplified target nucleic acids. The nanowires can sense these binding events and instantly convert them into electronic signals.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people 65 and older or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.